FDA cleared modified-risk claims. The smoke-free transformation is accelerating.
Record revenue, a surprise profit, and a debt load that changes everything.
The CFO already told you Q2 billing growth is running above a three-year high.
Value-added services up 25%+ and a $20B buyback. July 28 is the number that matters.
Industrial recovery plus AI power demand is an unusual combination for a chip company nobody was watching.
The market is pricing in failure. The data is telling a different story.
One of the S&P 500’s top stocks of 2026 just entered correction territory. The fundamental case hasn’t...
Revenue up 40% and a $7.7B backlog. The real debate is the valuation.
An 86% EPS beat today just made insurance the most interesting trade in the market.
A $10B Crinetics deal, a fifth commercial pillar, and Q2 earnings that will define the acquisition thesis.